Company Overview and News
InvestorPlace’s Laura Hoy recently discussed why Helios and Matheson Analytics (NASDAQ:HMNY), the 81.2% majority owner of MoviePass, is about to go to zero. HMNY stock has suffered catastrophically over the last year.
The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
On today’s episode of the Zacks Friday Finish Line, Associate Stock Strategists Ryan McQueeney and Ben Rains take on this week’s biggest stories, including MoviePass’ struggle to survive, the return of PC giant Dell to public markets, Tesla’s historic-yet-disappointing milestone, and Micron’s legal battle in China.
DVMT HMNY FINL VMW
Helios and Matheson Analytics’ (NASDAQ:HMNY) MoviePass pricing is increasing today with the introduction of “peak times” surcharges.
Things at movie ticket sales agent MoviePass has been sick, financially, and based on a new SEC filing will probably get worse, if that is possible. Despite some success it has had getting subscribers, it may run out of money soon. That leaves open who the possible buyers of its assets might be.
Shares of Helios and Matheson Analytics , the majority owner of MoviePass, plummeted nearly 30% on Monday on news that it filed a shelf offering to stay above water. It hopes to raise $1.2 billion in equity and debt securities to fund the venture, which now boasts three million subscribers but faces a growing number of challenges.
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN HMNY WFC.PRY WFC.PRX WFC.PRW WFC.PRV
When a company’s share price drops by more than 99% in less than a year, it’s time to take desperate measures. Helios and Matheson Analytics Inc. (NASDAQ: HMNY) could not be much more desperate.
As filed with the Securities and Exchange Commission on July 2, 2018 Registration No. 333-
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET